Paper Details

  1. Home
  2. Paper Details

Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase II trial.

Author: AnnalaM, AzadA A, BaconJ V W, BejaK, ChiK N, FerrarioC, FuS, GingerichJ R, HotteS J, IqbalN, KallioH M L, KhalafD J, LoG, NorthS A, NykterM, OngM, PezaroC J, RuetherJ D, SchönlauE, SipolaJ, SridharS S, TaavitsainenS, TranB, VandekerkhoveG, WadhwaD, WongA, WoodL A, WyattA W

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Cabazitaxel was associated with a higher clinical benefit rate in patients with ARPI-naive poor prognosis mCRPC.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Treatment of poor prognosis metastatic castration-resistant prostate cancer (mCRPC) includes taxane chemotherapy and androgen receptor pathway inhibitors (ARPI). We sought to determine optimal treatment in this setting. PATIENTS AND METHODS: This multicentre, randomised, open-label, pha...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.annonc.2021.03.205

データ提供：米国国立医学図書館（NLM）

Cabazitaxel: A New Hope in the Desert of Prostate Cancer Treatment?

The relentless battle against [prostate cancer] often requires innovative approaches to combat this challenging disease. This research explores the potential benefits of cabazitaxel, a chemotherapy drug, in the treatment of poor prognosis metastatic castration-resistant prostate cancer (mCRPC). The authors conducted a multicenter, randomized, open-label, phase II trial comparing cabazitaxel to either enzalutamide or abiraterone, both androgen receptor pathway inhibitors (ARPI). The results showed that cabazitaxel was associated with a higher clinical benefit rate compared to ARPI in these patients. However, there was no significant difference in overall survival or time to progression between the groups.

Navigating the Sands of Treatment Options: Unveiling New Possibilities

This study, like a caravan venturing into a vast desert, explores new frontiers in prostate cancer treatment. While cabazitaxel demonstrates a higher clinical benefit rate, further research is needed to fully understand its long-term impact on survival. The study also highlights the importance of considering individual factors, including circulating tumor DNA (ctDNA) abundance, to personalize treatment plans.

The Promise of Personalized Medicine: A Tailor-Made Approach to Cancer Treatment

This research reinforces the importance of a personalized approach to cancer treatment. The findings suggest that individual characteristics, such as ctDNA abundance, can influence treatment outcomes. This underscores the need for comprehensive evaluation and tailored therapies to optimize patient care and maximize therapeutic benefit.

Dr.Camel's Conclusion

This research, like a desert oasis offering hope in a challenging landscape, highlights the potential benefits of cabazitaxel in the treatment of poor prognosis mCRPC. While further research is needed, the findings offer a glimmer of hope for patients facing this difficult diagnosis. This study serves as a reminder that the journey towards effective cancer treatment is an ongoing one, fueled by innovation, personalized medicine, and the relentless pursuit of better outcomes.

Date :
  1. Date Completed 2021-06-28
  2. Date Revised 2021-09-02
Further Info :

Pubmed ID

33836265

DOI: Digital Object Identifier

10.1016/j.annonc.2021.03.205

Related Literature

Article Analysis
・Effective treatment of prostate cancer
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.